



Intermountain®
Heart Institute

Intermountain Medical Center

Overview of Advanced Mechanical Circulatory Support and Heart Transplantation

Bruce B Reid, MD Surgical Director

Artificial Heart Program/Heart Transplantation

Technology



Intermountain[®]
Heart Institute

Intermountain Medical Center

Embracing Progress



Intermountain[®]
Heart Institute

Intermountain Medical Center


Early Milestones in Cardiac Surgery



Intermountain[®]
Heart Institute

Intermountain Medical Center

1800s



“A surgeon who tries to suture heart wounds deserves to lose the esteem of his colleagues.”

Theodor Billroth
(1829 – 1894)




Intermountain[®]
Heart Institute

Intermountain Medical Center

Penetrating Cardiac Trauma



Dwight Harken, MD
1910-1993



Intermountain[®]
Heart Institute

Intermountain Medical Center

Closed Mitral Commissurotomy




Intermountain[®]
Heart Institute

Intermountain Medical Center

Alfred T. Blalock, MD

1899-1964



Johns Hopkins



Intermountain[®]
Heart Institute

Intermountain Medical Center

Helen B. Taussig, MD



Intermountain[®]
Heart Institute

Intermountain Medical Center

Helen B. Taussig, MD

1898 - 1986



Johns Hopkins University



Intermountain[®]
Heart Institute

Intermountain Medical Center

Helen B. Taussig, MD

1898 - 1986



Children with Tetralogy of Fallot exhibit bluish skin during episodes of crying or feeding.




"Tet spell"

ADAM.

Tetralogy of Fallot

Four abnormalities that result in insufficiently oxygenated blood pumped to the body



ADAM.



Intermountain[®]
Heart Institute


Intermountain Medical Center

BT Shunt

Blalock A, Taussig HB:

The surgical treatment of malformations of the heart in which there is pulmonary stenosis or pulmonary atresia.


JAMA 1945; 128:189



Intermountain
Heart Institute

Intermountain Medical Center

Vivien Thomas



Intermountain[®]
Heart Institute

Intermountain Medical Center

First Blalock-Taussig Shunt 1944



Intermountain[®]
Heart Institute

Intermountain Medical Center

OPERATION: Nov. 29, 1944

Dr. Alfred Blalock

Ether - Oxygen - Dr. Harnel

ANASTOMOSIS OF LEFT PULMONARY ARTERY TO LEFT SUBCLAVIAN ARTERY

This patient was an undernourished child who had cyanosis on frequent occasions. The diagnosis was pulmonary stenosis.

Under ether and oxygen, administered by the open method, an incision was made in the left chest extending from the edge of the sternum to the axillary line in the third interspace. The second and third costal cartilages were divided. The pleural cavity was entered. The left lung looked normal. No thrill was felt in palpating the heart and pulmonary artery. The left pulmonary artery was identified and was dissected free of the neighboring tissues. The left pulmonary artery seemed to be of normal size. The superior pulmonary vein, on the other hand, seemed considerably smaller than normal to me. I had hoped that the artery to the left upper lobe might be sufficiently long to allow an anastomosis, but this did not appear to be the case. The left subclavian artery was then identified and was dissected free of the neighboring tissues. The vertebral artery and the branches of the thyrocervical axis were doubly ligated and divided. The subclavian was so short that there would not have been sufficient length for our purposes, had this not been done. The subclavian artery was then ligated distal to the thyrocervical trunk. A bulldog clip was placed on the subclavian artery at a point just distal to its origin from the aorta. The subclavian artery was then divided just proximal to the ligature. Two bulldog clips were then placed on the left pulmonary artery, the first clip being placed at the origin of the left pulmonary artery, and the second clip being placed just proximal to the point where the artery entered the lung. There was ample space between these two clips for our purpose. A small transverse incision was then made in the wall of the pulmonary artery. By the use of china beaded silk on fine needles, an anastomosis was then performed between the end of the left subclavian artery and the side of the left pulmonary artery. A posterior row of sutures was placed first. There was practically no bleeding following the removal of the bulldog clips.

The anastomosis seemed to be a satisfactory one, and the main point of worry comes from the small size of the left subclavian artery. I was disturbed because I could not feel a thrill in the pulmonary artery after the clips were removed. I do not believe that this was due to any clot in the subclavian artery, because it seemed to pulsate vigorously. It is possible that it was due to a low pressure in the systemic circulation. I do not actually know what the systemic pressure was. Another possibility was that it might have been due to spasm of the subclavian artery. My only regret was that the subclavian artery was not bigger. It is possible that the increased red cell count in this patient may have predisposed to thrombosis.

(over)

Surgical Pioneers



Dr. Alfred Blalock

Vivien Thomas

*PHOTOS BY THE ALAN MASON CHESNEY MEDICAL
ARCHIVES OF THE JOHNS HOPKINS
MEDICAL INSTITUTIONS*



Intermountain.
Heart Institute

Intermountain Medical Center

Blue Babies

NEW YORK HERALD TRIBUNE, FRIDAY, FEBRUARY 15, 1946

'Blue Babies' Who Were Restored to Health and Doctors Who Did It



Herald Tribune—Blue Michael Rose, five and a half, of 2200 Boscobel Place, the Bronx



Herald Tribune—Blue Alan Beck, three and a half, of 1700 Sterling Place, Brooklyn



Herald Tribune—Anne Marilyn Eisenbaum, nine and a half, 80 Chester Street, Brooklyn



Herald Tribune—Kavallise Harry Goldzwig, seven, of 925 Fifty-seventh Street, Brooklyn

How 2 Doctors Give New Lives To Blue Babies

Blalock-Taussig Operation, First Tested on Dogs, Reroutes Flow of Blood

By Lester Grant

BALTIMORE, Feb. 14.—This is the story of the work of two doctors—a man from Georgia and a woman from Massachusetts—who met in Baltimore and combined their talents to save the lives of "blue babies."


The doctors are Alfred Blalock, forty-six, surgeon in chief at Johns Hopkins Hospital here and professor of surgery at the Hopkins Medical School, and Helen B. Taussig, forty-seven, physician in charge of the cardiac clinic of the Harriet Lane Home for Invalid Children, The Harriet Lane Home constitutes the pediatrics division of Johns Hopkins Hospital.

The surgery, known as the Blalock-Taussig operation, first was used on an infant on Nov. 29, 1944, its development since then is one of the most exciting stories in



Herald Tribune—Anne Dr. Alfred Blalock and Dr. Helen B. Taussig at Johns Hopkins Hospital in Baltimore

Switching Arteries Sidetracks Blood and Oxygen to Otherwise Starved Lungs



The "Blue" Babies' Blood Lacks Vital Oxygen Because the Artery (1) From the Heart to the Lung Is Constricted. By Severing an Artery of the Arm (2), Tying It Off (3) and Attaching It to the Lung Artery (4) the Constriction Is Bypassed.

By Robert D. Potter
Science Editor

A WOMAN's physician's courage, research and imagination, and the skill of one of the world's great surgeons have combined to bring hope that many "blue" babies hitherto considered doomed to early death—may be saved.

These babies are blue because they are suffering from a lack of oxygen in their blood streams, in a condition known as cyanosis. The artery from their heart to their lungs is so constricted that their blood never gets oxygen to make checks rosy.

Their lips are blue, and they can walk only a few feet without exhaustion. Doctors used to give them only a few surgical years to live.

But now medicine can give hope. . . . and now, for the first time, Nov. 29, 1944, Dr. Blalock, Professor of Surgery at Johns Hopkins University in Baltimore, has been conquering the "blue" baby mainly by rerouting an artery from the arm and making it carry blood to the lungs where it can receive its vital oxygen.

Nearly 70 operations have been performed on "blue" babies. In many cases almost miraculous recovery has come.

It is Dr. Blalock's fingers that wield the knife in the delicate operation that exposes the heart and transplants its vital arteries. That behind the brilliant operation of his hands is the research of Dr. Helen B. Taussig, Daughter of the late Prof. F. W. Taussig, world-famous Harvard room-

omist, Dr. Taussig had watched "blue" babies come to her heart clinic at Johns Hopkins Hospital.

In many cases she discovered that the artery leading to the lung from the heart was narrowed, that an insufficient supply of blood was reaching the lungs to receive its vital oxygen. Dr. Taussig reasoned that a surgical operation might be able to sidetrack the constriction and sidetrack blood into the lungs. On paper, when the diagram of the ar-

Saving our Doomed 'Blue' Babies



Six-Year-Old Mike Schirmer of Baltimore Could Walk Only Five Feet Without Resting Before the Operation. He Shows His "Ticky Zipper"—the Incision for the Operation.


the blood would pick up its life-giving oxygen. Then it would go back to the heart again to move onward through the body.

But could it be done? It is one thing to have a plumber rearrange a piping system and something quite different to lay bare the human heart, sever one of its main arteries, splice it for another main artery and sustain life in the patient in the process. Dr. Blalock said he would try.

Since the pioneer attempt the operation has been largely successful, although it is one filled with danger. Among the first 70 patients, 14 died. The odds are 5 to 1 for success.

Now that the news of Dr. Blalock's operation is known through the country the list of patients grows daily. Blue little Bonnie Stewart of Florida, daughter of a daddy killed on Seipan, went to Baltimore with her grandmother, Toby Bonnie walks and plays like other children.

The case of six-year-old Mike Schirmer—the boy with the "ticky zipper"—shows what can be done.



Little Bonnie Stewart of Florida is Another of the 70 Children Saved by the New Johns Hopkins Surgery.

was so hope that Mike could grow up. But then came new hope, for Dr. Blalock chooses the most convenient—usually the arm artery—operation of Dr. Blalock.

"They took him to the operating room and brought him back two hours later. It was a miracle.

"After only two weeks of convalescence he came home and he has been on the go ever since. If anyone wants anything he'll run and get it. He's up and down stairs 15 times a day. He climbs on benches and tables just for the joy of jumping off.

He waxes me out. But I love it. The Blalock-Taussig operation is not a simple one. It takes from six

branches of the pulmonary artery (to the lungs) are two large blood vessels. One connects the heart and the arm, the other the heart and the head. Dr. Blalock chooses the most convenient—usually the arm artery—and severs it. One end is clamped off and the other closed permanently.

The end nearest the heart is then spliced to the nearest branch of the pulmonary artery. The clamps are removed and the blood that would ordinarily flow to the arm goes into the lung. There it becomes enriched with vital oxygen and the baby's blue lips quickly begin to turn red.

What happens to the arm? Nature has provided other blood vessels which take up the blood load

Blalock and Taussig in London



Intermountain[®]
Heart Institute

Intermountain Medical Center



Legacy to Children



Intermountain[®]
Heart Institute

Intermountain Medical Center

Blalock-Taussig Shunt



The left subclavian artery is divided and connected to the left pulmonary artery. This allows blood to flow to the lungs to pick up oxygen. © 2004 - Duplication not permitted



Intermountain[®]
Heart Institute

Intermountain Medical Center

Johns Hopkins University



C. Walton Lillehei, MD

1918 - 1999

Donor
Cross Circulation




Donor Cross Circulation

Lillehei CW, Cohen
M, Warden HE, et al

The results of direct
vision closure of
ventricular septal
defects in eight
patients by means
of controlled cross
circulation.

Surg Gynecol
Obstet 1955;
101:446




Intermountain[®]
Heart Institute

Intermountain Medical Center

John H. Gibbon, MD

1903 - 1973

Pioneer in the
development of
extracorporeal
circulation



Intermountain[®]
Heart Institute

Intermountain Medical Center

Mass General



Intermountain[®]
Heart Institute

Intermountain Medical Center




Massive Pulmonary Embolus



Intermountain[®]
Heart Institute

Intermountain Medical Center


Early Heart Lung Machine



Intermountain[®]
Heart Institute

Intermountain Medical Center


Thomas J. Watson



Nothing so conclusively proves a man's ability to lead others as what he does from day to day to lead himself.

Thomas J. Watson Sr., Founder, IBM

Thomas J. Watson



"Our work is one of service."

--Thomas J. Watson, Sr

May 16, 1953

*Thomas Jefferson
University*


First successful open heart
surgery using
cardiopulmonary bypass



Intermountain[®]
Heart Institute

Intermountain Medical Center

Success



Intermountain
Heart Institute

Intermountain Medical Center


Heart Lung Machine



Intermountain[®]
Heart Institute

Intermountain Medical Center

Modern Cardiopulmonary Bypass



Intermountain[®]
Heart Institute

Intermountain Medical Center

Heart Transplantation

- “Thus saith the Lord God, ‘A new heart also will I give you, and a new spirit will I put within you; and I will take away the stony heart out of your flesh, and I will give you an heart of flesh.’” ‘
- Ezekial, chapter 36, verse 26



Intermountain
Heart Institute

Intermountain Medical Center

First Heart Transplant 1967

Moments in History

In December, 1967, a young woman, Denise Darvall, was walking across a street in Woodstock to buy a cake when a car struck her. She died in Grootse Schuur Hospital and in doing so achieved immortality by becoming the world's first heart donor when Christiaan Neethling Barnard transferred her heart into the chest of Louis Washkansky.

Cape Town has been witness to many historic moments since the day Van Riebeeck anchored in Table Bay. Few, if any, brought more limelight to the city than the heart transplant. For the surgeon, Dr Barnard, soon to be a household name throughout the world, "the heart is merely a pump". But for those who equated the heart with love and death, the transplant seemed close to a miracle.



Professor Chris Barnard, leader of the heart-transplant team, in a characteristic pose during one of his many press conferences.



First close-up photograph to be taken of Mr Louis Washkansky, who underwent the world's first heart-transplant operation, was taken by a surgeon using an Arno photographer's camera at Grootse Schuur Hospital, Mr Washkansky, whose condition was given as good, is being assisted to breathe by a respirator. 4.12.1967



"Mr Louis Washkansky, the 55-year-old Cape Town man whose life is being sustained today by the heart of a dead 25-year-old woman after the world's first successful heart transplant yesterday, is conscious in Grootse Schuur Hospital and in a satisfactory condition." Monday, 4th December 1967




Intermountain
Heart Institute

Intermountain Medical Center

Christiaan N. Barnard, MD



Norman E. Shumway, MD



Intermountain[®]
Heart Institute

Intermountain Medical Center

First Transplant in US 1968



© P. Baldwin



© Mike Baldwin/ Cornered

“OK, the old one’s in my right hand,
the donor’s in my left. Right?”

Heart Transplantation


- First performed in 1967—clinically useful in the early 80s
- Inherent limitations—lack of donors
- ~2000 transplants per year; 3200 listed (many patients die on the waiting list)
- 15-20 transplants at IMC per year
- The majority of transplant recipients in the modern era are “bridged” to the procedure with an LVAD



Intermountain
Heart Institute

Intermountain Medical Center

Heart Transplants Reported per Year




ISHLT 2012

J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095

NOTE: This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, the presented data may not mirror the changes in the number of heart transplants performed worldwide

Kaplan-Meier Survival by Era

(Transplants: January 1982 - June 2010)



ISHLT 2012

J Heart Lung Transplant. 2012 Oct; 31(10): 1045-1095

Post-Heart Transplant Morbidity for Adults

Cumulative Prevalence in Survivors at 1, 5 and 10 Years Post-Transplant (Follow-ups: April 1994 - June 2009)

<u>Outcome</u>	<u>Within 1 Year</u>	<u>Total N with known response</u>	<u>Within 5 Years</u>	<u>Total N with known response</u>	<u>Within 10 Years</u>	<u>Total N with known response</u>
Hypertension	73.2%	(N = 24,229)	93.1%	(N = 10,485)	97.4%	(N = 2,238)
Renal Dysfunction	26.8%	(N = 25,254)	31.1%	(N = 12,146)	36.8%	(N = 3,681)
<i>Abnormal Creatinine < 2.5 mg/dl</i>	18.1%		21.0%		24.3%	
<i>Creatinine > 2.5 mg/dl</i>	7.0%		7.3%		6.2%	
<i>Chronic Dialysis</i>	1.5%		2.3%		4.8%	
<i>Renal Transplant</i>	0.3%		0.5%		1.5%	
Hyperlipidemia	58.1%	(N = 25,572)	87.8%	(N = 11,800)	93.3%	(N = 2,659)
Diabetes	27.4%	(N = 25,292)	36.6%	(N = 11,154)	38.5%	(N = 2,401)
Cardiac Allograft Vasculopathy	7.8%	(N = 22,853)	31.0%	(N = 8,197)	51.8%	(N = 1,830)



ISHLT

J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141

Copyright 2003 by Randy Glasbergen.
www.glasbergen.com



“Your insurance won’t pay to transplant a human heart or even a baboon heart, so we’ll be using an artichoke heart.”

LIFE

THE 21st
CENTURY
FAMILY
NEW SHAPES,
OLD VALUES



Lisa waits for a heart

50,000 Americans
need new hearts.
Most will never
get one. Who lives?
Who dies?
Special report



November 1999/\$3.99 11 >
0 70989 10099 2
DISPLAY UNTIL NOVEMBER 15

The Magnitude of CHF

- 6 million suffer from heart failure: 550,000 new cases per year
- Only form of heart disease increasing in prevalence
- 262,000 deaths per year
- Incidence doubles each decade after 40
- 1 in 5 over age 40 have heart failure
- One year mortality is 28% in men over 75
- Most common cause of hospitalization in patients over 65



Intermountain
Heart Institute

Intermountain Medical Center

Economic Impact of CHF




- Annual cost of \$30 billion in U.S.
- Most costly diagnosis in the Medicare population
- More costly than all forms of cancer combined
- 11 million office visits; 3.5 million hospitalizations
- Average total annual cost in Utah of \$46 million dollars (79% paid for by the government)*
- \$19,843 per hospitalization in Utah*


**Utah Department of Health*

Heart Failure: The Final Cardiovascular Disease

Coronary deaths are down by half




But heart failure has almost tripled





Enhanced survival in other CV diseases leads to expansion of HF Population

Natural History of Heart Failure



Adapted from Bristow, MR Management of Heart Failure, *Heart Disease: A Textbook of Cardiovascular Medicine*, 6th edition, ed. Braunwald et al.

Total Artificial Heart




1969 - first artificial heart to be implanted into a human (Dr. Denton Cooley).

The patient was sustained by the device for 3 days, but only lived for 36 hours post transplantation.

The patient's widow accused Cooley of making her husband the "unfortunate victim of human experimentation."

Barney Clarke


1982 – Barney Clarke with Mrs. Clarke after his initial recovery.



Intermountain
Heart Institute

Intermountain Medical Center

Barney Clarke




Jarvik, DeVries and Kolff examine Clarke's artificial heart after autopsy.



Intermountain[®]
Heart Institute

Intermountain Medical Center

Total Artificial Heart



REMATCH Summary



- NEJM November 2001
- LVAD vs. optimal medical management
- LDS Hospital - largest enrollment in the country
- Landmark trial leading to FDA approval
- 129 patients with NYHA Class IV CHF ineligible for transplant
- 48% risk reduction of death with LVAD
- 52% vs. 25% survival at 1 year
- 24% vs. 8% survival at 2 years
- Improved quality of life (LVAD patients felt better, less depressed, more mobile and active)



Intermountain[®]
Heart Institute

Intermountain Medical Center

HeartMate II – FDA approved for DT



NEJM, Nov. 2009

FDA approved Jan. 20, 2010

TRIAL SUMMARY:

- Total of 200 patients
- Median age of 62 years (range 26 to 81)
- Mean LVEF of 17%
- 77% of patients receiving IV inotropes
- 2:1 Randomization HM II vs. HM XVE (stopped at mid-study point due to favorable results)
- All 200 patients were followed for at least 2 years or until death, transplantation or device explantation
- QOL improvement to NYHA Class I - II




Intermountain[®]
Heart Institute

Intermountain Medical Center

HM II DT – Trial Data

	HM II	HM XVE
Survival @ 2 years	58%	24%
Median duration of support	1.7 years	0.6 years
Relative Risk (95% CI)		
Device repair or replacement	0.06	0.51
Stroke	0.13	0.22
LVAD-related infection	0.48	0.90
Bleeding requiring surgery	0.23	0.29
Rehospitalization	2.64	4.25

Former Vice President Dick Cheney






- HeartMate II implant August 10, 2010 as BTT
- 1.5 years of support
- Successful bridge to transplant
- Age 70

“It’s brought me back from end-stage heart failure,” says Cheney, who has suffered five heart attacks, the first at age 37. “I was in bad shape 14 months ago. Now I’m back to leading a relatively normal life. I fish, hunt a little bit, write books, (am) able to travel.”

Bridge to Transplantation (BTT)


An increasing percentage of patients listed for cardiac transplantation require VAD support as a bridge.





-  Bridge requiring VAD/Artificial Heart
-  Traditional Transplantation

OUTCOMES AT OUR CENTER:
HM II Survival to Transplant: 100%

Bridge to Transplantation (BTT)



-  Bridge requiring VAD/Artificial Heart
-  Traditional Transplantation


Recent transition to HeartWare HVAD with excellent outcomes as bridge

Mechanical Circulatory Support



Short Term / Emergency

- Time frame: hours to days
- Rapid MCS for cardiogenic shock, post cardiectomy failure, or during high-risk Cath Lab procedures



Bridge to Transplant (BTT)

- Time frame: months to years
- Temporary implanted MCS for patients waiting for a donor heart to become available



Destination Therapy (DT)

- Time frame: Permanent (years)
- Long-term implanted MCS for patients who are not eligible for a heart transplant





Intermountain[®]
Heart Institute


Intermountain Medical Center

HeartWare HVAD™

- Centrifugal pump
- One moving part
- Short integrated inflow cannula
- 10mm outflow graft
- Dual motor stators
- Thin, flexible driveline
- Sewing ring



HeartWare HVAD



- Inflow cannula integrated with device
- Small pump housing: 2 inch outside diameter, displaced volume of 50 cc
- Magnetically suspended impeller, only moving part (increased durability potential)
- Intrapericardial – no pump pocket
- Requires warfarin (INR: 2.0 - 2.5)
- Approved for use in Europe
- Destination Therapy clinical trial in U.S. (ENDURANCE)
- UAHP: 43 implants to date





Intermountain[®]
Heart Institute

Intermountain Medical Center

Unique Features


- No abdominal surgery or pump pocket
- Fits in the pericardial space
- Anatomically fits smaller patients
- Less surgery; potentially minimizes blood transfusions
- Novel impeller design enables excellent hemodynamics
- Accurate flow estimation
- Log files enable flow and power waveform analysis



Interior of pump shown after 427 days of support in human patient



IMPELLER



PUMP HOUSING

- Impeller only moving part
- Completely suspended by a combination of passive magnets and hydrodynamic thrust bearings
- Never touches pump housing

HeartWare HVAD



Intermountain[®]
Heart Institute

Intermountain Medical Center

MCS Case Review


- 68 year male with 12 year history of IDC
- Sudden death in August 2009
- Discharged with BiV ICD
- Progressive deterioration to class III/IV
- Multiple hospitalizations over the following year
- Outpatient dobutamine
- Multidisciplinary review to assess candidacy for DT LVAD
- Enrolled in ENDURANCE trial—randomized to receive the HeartWare HVAD
- 3rd HVAD implant in the United States for DT

FR 52Hz
18cm

2D
76%
C 50
P Off
Gen




POST RPM 2500



JPEG

PAT T: 37.0C
TEE T: 39.3C

*** bpm



Intermountain Medical Center





Postoperative Day #1




Intermountain[®]
Heart Institute

Intermountain Medical Center

3 months later...




Improvements in Survival



Adoption of Technology

PERCENT OF
J.S. HOUSEHOLDS


CONSUMPTION SPREADS FASTER TODAY



Intermountain[®]
Heart Institute

Intermountain Medical Center

Technology Adoption



Automobile



Intermountain[®]
Heart Institute

Intermountain Medical Center

Automobile



Intermountain[®]
Heart Institute

Intermountain Medical Center

Automobile

- Ford Model T
- 1908 – 1927
- First affordable automobile
- Mass production
- Moving assembly line: every three minutes
- 20 horsepower 1.7 L 4 cylinder engine
- Top speed ~40 mph



Automobile

- Most influential car of the 20th Century
- Widespread adoption worldwide
- 50% of all cars in 1920
- 1909: 10,666 produced and sold for \$825 (\$21,650 in 2015)
- 1925: 1.9 million sold for \$260 (\$3,500 today)



Intermountain
Heart Institute

Intermountain Medical Center

Automobile



Intermountain[®]
Heart Institute

Intermountain Medical Center

Automobile



Aviation



Intermountain[®]
Heart Institute

Intermountain Medical Center

Aviation



Intermountain[®]
Heart Institute


Intermountain Medical Center

Aviation



Intermountain[®]
Heart Institute

Intermountain Medical Center



ter

Internet




Intermountain[®]
Heart Institute

Intermountain Medical Center




Life Expectancy – Pancreatic Cancer

- Best case scenario
 - Node negative
 - Clear margins at surgical resection (Whipple)
- 20% survival at 5 years for Stage I
- 10% survival at 1 year for all stages



Who and When?



Class III

- 25% of HF Patients
- Frequent hospitalizations
- Worsening symptoms despite drug therapy
- Significant opportunity for new therapies

— Survival Rate
..... Hospitalizations

Adapted from Bristow, MR Management of Heart Failure, *Heart Disease: A Textbook of Cardiovascular Medicine*, 6th edition, ed. Braunwald et al.

Evaluation Criteria

Consider an evaluation when *three* of the following indications are present:

- Class III – IV heart failure symptoms
- Inability to walk < 1 block without dyspnea
- Sodium < 136 mEq/L
- BUN > 40 mg or Cr > 1.8 mg/dL
- ACE/ ARB/ BB intolerance
- Diuretic dose > 1.5 mg/kg/d
- 1 HF admit in the past 6 months
- No clinical improvement with CRT



Intermountain
Heart Institute

Intermountain Medical Center

Steps to Clear the Adoption Chasm

- Viable tool for management of CHF
- Improve patient selection and perioperative management
- Fewer complications and shorter length of stay
- Smaller, less expensive, more durable devices
- 100% success as a bridge to transplantation
- 5 - 10 year DT survival equal to transplantation
- Enhance patient length and quality of life



Intermountain[®]
Heart Institute

Intermountain Medical Center

Contact Information

Bruce B Reid, MD

Office: 801-507-3600

Cell: 801-719-8253

24 Hour Hotline: 801-507-LVAD

Bruce.Reid@imail.org



Intermountain[®]
Heart Institute

Intermountain Medical Center



Increasing the **LENGTH** and **QUALITY** of life for patients with heart failure...